Skip to content

Net Income at other companies

LivaNova logo
LivaNovaLIVN
$22.29M+107%
ICU Medical logo
ICU MedicalICUI
$30.13M+295%
Edwards Lifesciences logo
Edwards LifesciencesEW
$380.7M+6.3%
United Therapeutics logo
United TherapeuticsUTHR
$274.9M-14.7%
OSI Systems logo
OSI SystemsOSIS
$40.22M-2.2%

Other financials

Income statement

See full
Revenue$173.9M+21.2%
Gross profit$101.2M+14.7%
Operating income$13.3M-51.5%
EPS (diluted)$0.20-71.4%

Balance sheet

See full
Cash & equivalents$461.7M+48.9%
Total debt$409.9M+505%
Total equity$494.0M+85.5%
Total assets$1.4B+71.3%

Cash flow

See full
Operating cash flow$24.5M+959%
CapEx$36.7M+35.6%
Free cash flow-$12.1M+59.4%

Valuation

See full
Market cap$2.55B+50.6%
Enterprise value$2.5B+66.0%
P/E14.8×-19.8×
P/S+0.5×

Profitability

See full
Gross margin59.1%-0.4pp
Operating margin14.9%+4.1pp
Net margin27%+17.0pp
FCF margin23.8%

Returns & leverage

See full
Return on equity45.2%+22.2pp
Debt / equity0.8×+0.6×
Current ratio6.7×-2.4×

Where this comes from

Reported directly by TransMedics Group, Inc. in its filing.

Tagged under the XBRL concept us-gaap:NetIncomeLoss.

The official record: TransMedics Group, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about TransMedics Group, Inc.'s net income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is TransMedics Group, Inc.'s net income?
TransMedics Group, Inc. (TMDX) reported net income of $7.32M in Q1 2026.
How has TransMedics Group, Inc.'s net income changed year-over-year?
TransMedics Group, Inc.'s net income decreased by 71.5% year-over-year, from $25.68M to $7.32M.
What is the long-term trend for TransMedics Group, Inc.'s net income?
Over 3 years (2021 to 2025), TransMedics Group, Inc.'s net income has grown at a 62.7% compound annual growth rate (CAGR), from -$44.22M to $190.29M.
What does net income mean?
The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.